Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 8/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.49 |
| ▸ | FGFR4 | P22455 | 5/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.49 |
| ▸ | KDR | P35968 | 5/20 | 0.49 |
| ▸ | FLT1 | P17948 | 4/20 | 0.49 |
| ▸ | FLT4 | P35916 | 4/20 | 0.49 |
| ▸ | SRC | P12931 | 11/20 | 0.46 |
| ▸ | LYN | P07948 | 9/20 | 0.46 |
| ▸ | BTK | Q06187 | 7/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13593185 | 0.88 | BTK (0.51) | FGFR1SRCLYNBTK | |
| SCHEMBL6639949 | 0.86 | FGFR1 (0.63) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL13593203 | 0.84 | SRC (0.50) | FGFR1FGFR4SRCLYNBTK | |
| SCHEMBL13593190 | 0.83 | SRC (0.48) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL13593183 | 0.82 | BTK (0.48) | FGFR1FGFR4SRCLYNBTK | |
| SCHEMBL4325359 | 0.82 | BTK (0.52) | SRCLYNBTK | |
| SCHEMBL13593188 | 0.81 | BTK (0.48) | SRCLYNBTK | |
| SCHEMBL13593213 | 0.79 | BTK (0.53) | SRCLYNBTK | |
| SCHEMBL4413736 | 0.78 | BTK (0.55) | SRCLYNBTK | |
| SCHEMBL6640513 | 0.77 | FGFR1 (0.66) | FGFR1FGFR2FGFR4FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312321-A1 | COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS | IRM LLC (BM) | 2009-12-17 | — | — | US | disclosed |
| US-20090312321-A1 | COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS | IRM LLC (BM) | 2009-12-17 | — | — | US | disclosed |
| WO-2007136465-A2 | COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS | IRM LLC (BM) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312321-A1 | COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS | PTK2B, SGK2, FRK | FGFR1 92/4885FGFR2 102/4885FGFR4 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.